Zhitong Finance App News, Chuangsheng Group-B (06628.HK) issued an announcement. The board of directors of the company is pleased to announce that the phase I/II clinical trial (Transtar102) G cohort of osemitamab combined with navulimab and capox as first-line treatment for gastric or gastroesophageal adenocarcinoma (TranStar102) is based on updated efficacy analysis of CLDN18.2 and PD-L1 expression. The findings were presented as a poster (abstract number: #299P) at the European Society of Medical Oncology Asian Annual Meeting 2025 (ESMO Asia Congress 2025) in Singapore.

Zhitong Finance App News, Chuangsheng Group-B (06628.HK) issued an announcement. The board of directors of the company is pleased to announce that the phase I/II clinical trial (Transtar102) G cohort of osemitamab combined with navulimab and capox as first-line treatment for gastric or gastroesophageal adenocarcinoma (TranStar102) is based on updated efficacy analysis of CLDN18.2 and PD-L1 expression. The findings were presented as a poster (abstract number: #299P) at the European Society of Medical Oncology Asian Annual Meeting 2025 (ESMO Asia Congress 2025) in Singapore.